Patents by Inventor Bryan Bednarz
Bryan Bednarz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240066156Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: ApplicationFiled: June 30, 2023Publication date: February 29, 2024Inventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Patent number: 11730834Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: GrantFiled: June 29, 2020Date of Patent: August 22, 2023Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Patent number: 10921395Abstract: A system and method for providing virtual real-time MRI-guidance for a biopsy outside of a conventional MRI scanner is described. MR images and ultrasound images of a region of a patient's body are simultaneously acquired during a pre-biopsy procedure. Respiratory states that the patient may experience during the biopsy are then determined from the acquired ultrasound images, and each respiratory state is associated with corresponding MR images. The MR images are indexed with their corresponding respiratory state. Ultrasound images are then acquired of the patient during a biopsy procedure. The respiratory state of the patient is determined from the ultrasound images, and the corresponding indexed MR images are displayed.Type: GrantFiled: January 12, 2018Date of Patent: February 16, 2021Assignee: GE PRECISION HEALTHCARE LLCInventors: Thomas Kwok-Fah Foo, Jhimli Mitra, Bo Wang, Lowell Scott Smith, David Martin Mills, Warren Lee, James Hartman Holmes, Bryan Bednarz, Roberta Marie Strigel
-
Publication number: 20200330621Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: ApplicationFiled: June 29, 2020Publication date: October 22, 2020Inventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Publication number: 20200330567Abstract: A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula: wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.Type: ApplicationFiled: July 2, 2020Publication date: October 22, 2020Inventors: Jamey Weichert, Paul M. Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz
-
Patent number: 10751430Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: GrantFiled: July 25, 2017Date of Patent: August 25, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Patent number: 10736949Abstract: A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula: wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.Type: GrantFiled: July 18, 2017Date of Patent: August 11, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Paul M. Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz
-
Publication number: 20190219647Abstract: A system and method for providing virtual real-time MRI-guidance for a biopsy outside of a conventional MRI scanner is described. MR images and ultrasound images of a region of a patient's body are simultaneously acquired during a pre-biopsy procedure. Respiratory states that the patient may experience during the biopsy are then determined from the acquired ultrasound images, and each respiratory state is associated with corresponding MR images. The MR images are indexed with their corresponding respiratory state. Ultrasound images are then acquired of the patient during a biopsy procedure. The respiratory state of the patient is determined from the ultrasound images, and the corresponding indexed MR images are displayed.Type: ApplicationFiled: January 12, 2018Publication date: July 18, 2019Inventors: Thomas Kwok-Fah Foo, Jhimli Mitra, Bo Wang, Lowell Scott Smith, David Martin Mills, Warren Lee, James Hartman Holmes, Bryan Bednarz, Roberta Marie Strigel
-
Publication number: 20180021461Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: ApplicationFiled: July 25, 2017Publication date: January 25, 2018Inventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Publication number: 20180015154Abstract: A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula: wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.Type: ApplicationFiled: July 18, 2017Publication date: January 18, 2018Inventors: Jamey Weichert, Paul M. Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz